CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.

AML patients at the extremes of older age derive benefit from VEN-HMA regimen

Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia.

May 10, 2024

Rising Share of New HIV Cases in Young Latinos Leads to Call for Targeted Funding

Four months after seeking asylum in the U.S., Fernando Hermida began coughing and feeling tired. He thought it was a cold. Then sores appeared in

June 27, 2024

Clinical Challenges: Rising Steatotic Liver Disease Prevalence

As rates of obesity and diabetes increase in the U.S. and worldwide, so too does the prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD, recently

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.